Investing in EBOS Group (NZSE:EBO) five years ago would have delivered you a 104% gain
When we invest, we're generally looking for stocks that outperform the market average. Buying under-rated businesses is one path to excess returns. For example, long term EBOS Group Limited (NZSE:EBO) shareholders have enjoyed a 75% share price rise over the last half decade, well in excess of the market decline of around 12% (not including dividends). On the other hand, the more recent gains haven't been so impressive, with shareholders gaining just 19%, including dividends.
Now it's worth having a look at the company's fundamentals too, because that will help us determine if the long term shareholder return has matched the performance of the underlying business.
Check out our latest analysis for EBOS Group
In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).
Over half a decade, EBOS Group managed to grow its earnings per share at 9.2% a year. This EPS growth is slower than the share price growth of 12% per year, over the same period. This suggests that market participants hold the company in higher regard, these days. And that's hardly shocking given the track record of growth.
The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image).
This free interactive report on EBOS Group's earnings, revenue and cash flow is a great place to start, if you want to investigate the stock further.
As well as measuring the share price return, investors should also consider the total shareholder return (TSR). Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. As it happens, EBOS Group's TSR for the last 5 years was 104%, which exceeds the share price return mentioned earlier. This is largely a result of its dividend payments!
It's nice to see that EBOS Group shareholders have received a total shareholder return of 19% over the last year. That's including the dividend. That gain is better than the annual TSR over five years, which is 15%. Therefore it seems like sentiment around the company has been positive lately. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Consider risks, for instance. Every company has them, and we've spotted 1 warning sign for EBOS Group you should know about.
If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: many of them are unnoticed AND have attractive valuation).
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on New Zealander exchanges.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Billionaire Warren Buffett Is Buying Shares of a Mystery Stock: Here's Everything We Know
Berkshire Hathaway's first-quarter 13F contained a confidential treatment tag, which means Warren Buffett is building up a position in secrecy. Berkshire's first-quarter operating results provide a big clue that helps narrow down the sector(s) where this mystery stock can be found. While a former holding may be Buffett's mystery stock, a handful of large-scale companies ($50 billion-plus in market cap) from a specific sector could be the right answer. 10 stocks we like better than Berkshire Hathaway › Despite an endless sea of earnings reports and economic data releases, there are few events more anticipated by the investing community than the quarterly filing of Berkshire Hathaway's (NYSE: BRK.A)(NYSE: BRK.B) Form 13F with the Securities and Exchange Commission (SEC). A 13F provides investors with a snapshot of which stocks Wall Street's leading asset managers have been buying and selling, and it has to be filed no later than 45 calendar days following the end to a quarter. In other words, Berkshire's 13F lifts the hood for professional and everyday investors and allows them to see which stocks Buffett purchased and sold. Thanks to Berkshire's May 15-filed 13F, along with various other regulatory filings, we know that Buffett was a buyer of 13 stocks during the March-ended quarter, as well as a seller of eight stocks. Even though the Oracle of Omaha has been a net-seller of equities for 10 consecutive quarters, there's something about knowing which stock(s) Buffett is buying that tugs on the heartstrings and pocketbooks of investors. But what really stood out about Berkshire Hathaway's first-quarter 13F filing with the SEC was the attached confidential treatment clause. On rare occasion, select money managers (often prominent billionaire investors) can request confidential treatment from regulators to not report one or more existing positions on their quarterly filed 13F. The reason a fund manager would request this is because investors would pile in and drive up the share price if the position were publicly revealed. If a high-profile money manager with a sizable Wall Street following can quietly build up their stake in a public company, they can likely do so at an advantageous price. Over the last decade, Warren Buffett has leaned on this confidential treatment provision a couple of times. Most recently, Berkshire's billionaire chief began building up a large position in property and casualty insurer Chubb (NYSE: CB) under the secrecy of the confidential treatment tag. Between July 1, 2023 and March 31, 2024, Buffett green-lit the purchase of nearly 26 million shares of Chubb, which was worth about $6.7 billion as of the end of March 2024. In the two trading days after this position was unmasked in mid-May 2024, Chubb stock rallied by more than $21 per share. Although Warren Buffett is being allowed to build up his position in secrecy, select filings from Berkshire Hathaway can help narrow down which stock(s) its billionaire chief is buying. For example, when Buffett has previously requested the confidential treatment tag, it's been for a sizable purchase (often a $4 billion to $8 billion stake). Considering that Buffett's company would absolutely be required to file a Form 4 with the SEC if its stake topped 10% (this figure is often 5% for beneficial owners), we know it has to be a large business. While a relatively inexpensive, brand-name company like Stanley Black & Decker might speak to Warren Buffett's knack for understanding consumer behaviors, it's only a $10 billion company. The company the Oracle of Omaha is secretly investing in likely has a market cap of $50 billion or considerably larger. This would allow Berkshire to invest billions of dollars without surpassing a roughly 5% to 10% stake. In addition to knowing that Buffett is buying shares of a big company, Berkshire Hathaway's first-quarter operating results and 13F help us pinpoint which area of focus this company can be found. Each quarter, Berkshire Hathaway's operating results provide a comparative breakdown of its cost basis, net unrealized gains, and fair value for its three investment areas of focus. By examining Berkshire's cost bases in these three areas, and comparing to the company's buying and selling activity via its 13F, we can put two and two together to figure out where Warren Buffett is doing his buying. In the "Banks, insurance and finance" category, Berkshire's cost basis fell from $15.71 billion in the fourth quarter (Q4 2024) to $14.27 billion in the March-ended quarter (Q1 2025). This drop is explained by the ongoing selling activity in Bank of America, as well as the disposition of Berkshire's stake in Citigroup. The second category, "Consumer products," showed a cost basis increase from $12.66 billion in Q4 2024 to $13.76 billion in Q1 2025. This can be entirely explained by Buffett's aggressive purchase of spirits stock Constellation Brands. The third category is "Commercial, industrial and other," whose cost basis jumped from $47.14 billion in Q4 2024 to $49.1 billion in Q1 2025. With only a few hundred million dollars in purchases for this broad-based category via Berkshire's 13F, it's clear that Buffett's mystery stock resides in this category. Lastly, we also know it's not any of Berkshire's existing holdings, since any buying activity would have shown up in the 13F or via Form 4 filings with the SEC. At the same time, there's plenty we can make logical guesses about, but don't know with any certainty. Arguably the biggest issue is that the "Commercial, industrial and other" segment comprises a boatload of potential sectors, including technology, healthcare, energy, and industrials. Almost 280 publicly traded companies have a market cap of at least $50 billion, and 136 of these companies can be traced back to the tech, healthcare, energy, and industrial sectors. That's a lot of dart-throwing! Historically, we know that Buffett isn't a huge fan of healthcare stocks, mainly because of the time and attention needed to keep up on clinical studies and Food and Drug Administration approvals. Something similar can be said about technology stocks, whose innovations aren't often fully understood by the Oracle of Omaha. For instance, even though Apple is one of Wall Street's most innovation-driven tech stocks, Buffett's attraction to Berkshire's No. 1 holding by market value has everything to do with its premier capital-return program and customers' loyalty toward Apple's physical products, including iPhone, Mac, and iPad. With this being said, it's unlikely to be a tech stock. Removing tech and healthcare leaves 54 potential stocks Buffett could be purchasing in secret in either the energy or industrial sectors. Though purchasing an energy stock in secret is more plausible than a tech stock in Buffett's portfolio, it's still unlikely. Energy has rarely played a large role in Berkshire's investment portfolio dating back to the start of the century. At the moment, combined investments in Chevron and Occidental Petroleum have given Buffett's company some of its largest energy exposure of the century. With two integrated oil and gas companies already among Berkshire's largest holdings, the addition of a third large energy stock seems improbable. The signs would appear to point to an industrial sector company, which would speak to Buffett's roots of investing in American manufacturing companies. Last month, I laid out my case why United Parcel Service (NYSE: UPS) is most likely the secret stock Warren Buffett is buying. UPS is a former Buffett stock that maintains clear-cut competitive advantages, has a robust capital-return program, and is historically cheap. However, there are other potentially inexpensive industrial stocks that I can't eliminate as possible purchase candidates. For instance, UPS rival FedEx (NYSE: FDX) is another logical buy candidate. Logistics companies represent the heart of the American economy, and Buffett has strongly cautioned investors not to bet against America. In recent quarters, FedEx has found itself on better financial footing than UPS. Though Buffett hasn't made a sizable investment in a defense company in a long time, Lockheed Martin (NYSE: LMT) might make sense. Lockheed losing out on a contract to build the next-generation of fighter jets for the Air Force to Boeing has created a temporary price dislocation that might speak to Berkshire's billionaire chief. It could even be something as simple as heavy construction giant and Dow Jones Industrial Average component Caterpillar (NYSE: CAT). While Buffett isn't a fan of mining companies, he's also not oblivious to companies like Caterpillar that offer large-scale competitive advantages. Buffett's mystery stock is a big (brand-name) company that isn't listed in Berkshire's 13F, and it's more than likely a company you'll find in the industrial sector. But narrowing it down any more than this is a guessing game. Before you buy stock in Berkshire Hathaway, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Berkshire Hathaway wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,538!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $869,841!* Now, it's worth noting Stock Advisor's total average return is 789% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Citigroup is an advertising partner of Motley Fool Money. Bank of America is an advertising partner of Motley Fool Money. Sean Williams has positions in Bank of America. The Motley Fool has positions in and recommends Apple, Bank of America, Berkshire Hathaway, Chevron, and FedEx. The Motley Fool recommends Constellation Brands, Lockheed Martin, Occidental Petroleum, and United Parcel Service. The Motley Fool has a disclosure policy. Billionaire Warren Buffett Is Buying Shares of a Mystery Stock: Here's Everything We Know was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
10 hours ago
- Forbes
The Age Of Digital Divination
Warren Buffett If you could be in the 99th percentile in one of these two skills, and just 55th percentile in the other skill, which would you pick? One is a visionary who can predict ten years ahead—the year 2035—with perfect clarity. Interest rates. Gold prices. Fashion. Presidents and prime ministers. The other choice is a 99th percentile detective, a star at separating signals from noise, but who is only 55th percentile good at ten-year forecasts. At first blush, one might be tempted to choose the visionary's skills. Market history shows that every rolling ten-year period produces a few investments that go up 500x or more. I have dreams (and regrets) that it's 2018 and I just mortgaged my home and liquidated my retirement funds to bet it all on Nvidia. Of course I didn't do that. My bad: I truly liked Nvidia and its CEO Jensen Huang 15 years ago. My mistake was not looking deeper, to find signals in the noise. The signals pointed to Nvidia in 2010 and 2015. They screamed buy Nvidia! after 2018. I have a hunch that AI's ten-year forecasting powers will disappoint us, now and for a long time. But AI's power to separate signals from noise along the way will astonish us. That's why we need to jump in and master AI now. So we can profitably detect signals in the noise of tariffs, war drums, hype and gloom. When Warren Buffett, known as the Oracle of Omaha, announced his retirement in May, many asked if it was likely, or even possible, to see another investor in his league. Buffett began his stock-picking career in the mid-1950s, working out of his modest house. His original investors were family and friends, and Buffett at the time was a pure value investor following the principles of his Columbia Business School lecturer Benjamin Graham. Buffett bought stocks that were heavily discounted to their intrinsic value. Out of fashion. Dirt cheap. Between 1957 and 1968, Buffett's small private fund reportedly delivered an average annual return of 25%. In 1965, Buffett acquired a struggling textile company, Berkshire Hathaway, and grew it into the world's most valuable public holding company. Over six decades, Berkshire produced a 19.9% compound annual return, roughly twice the S&P's average over the same period. One thousand dollars invested in Berkshire when the Rolling Stones' '(I Can't Get No) Satisfaction' topped the pop charts would be $54 million today. What if you had invested in the S&P index instead for 60 years? Sorry, $304,000. For the entirety of Buffett's extraordinary run, he avoided making predictions about the market or the future. In 1965, Toyota was building a reputation for small, reliable cars while Singapore was a startup nation with a new leader. Nowhere did Buffett predict that Toyota would become the world's top car company by sales. Buffett never predicted Singapore's rise to become one of the world's wealthiest cities per capita. He didn't foresee the Soviet Union's collapse or the rise of China. He said nothing about personal computers, the Web, or smartphones. He only became an Apple investor after it had turned into a cash-generating monster. Buffett's superpower was not predicting the future. It was detecting signals in the noise. Upon Buffett's retirement, Wall Street Journal columnist Jason Zweig wrote 'Why There Will Never Be Another Warren Buffett.' Zweig cited three Buffett superpowers: 1. Pattern recognition developed over 70 years and the careful reading of an estimated 100,000 financial reports. 2. A memory that 'is almost supernatural.' 3. Unparalleled access to financial information. Buffett was a one-man AI machine long before AI. Zweig is correct in saying there will never be another Buffett. The investing game will have moved on. But the new AI-armed investors will separate themselves from the pack exactly the way Buffett did: Seeing not the future, but signals in the noise.
Yahoo
16 hours ago
- Yahoo
Dr. Cockrell Joins Cutting-Edge Foot and Ankle Clinic in Nashville
Nashville-Davidson, June 05, 2025 (GLOBE NEWSWIRE) -- Nashville-Davidson, Tennessee - Cutting-Edge Foot and Ankle Clinic, led by podiatrists Dr. David Farnen and Dr. Yerusalem Lanier, along with nurse practitioner Morgan Hubble and physician assistant Rojin Abdullah, announced the addition of Dr. Gary Cockrell to its expanding and highly skilled medical staff. With convenient locations in Nashville and Brentwood, the practice continues its mission to provide advanced, comprehensive foot and ankle care to patients throughout the greater Middle Tennessee region. Dr. Cockrell brings more than 32 years of experience in podiatric medicine and surgery, making him one of the most seasoned specialists in the entire region. He is board-certified in foot and ankle surgery and holds diplomate status from the American Board of Foot and Ankle Surgery, underscoring his advanced surgical expertise. A native of Virginia, Dr. Cockrell earned a bachelor of science degree in animal science from Virginia Tech in 1979, with a minor in biology. He received his doctor of podiatric medicine degree from the California College of Podiatric Medicine in San Francisco in 1988. Following medical school, he completed a rigorous podiatric surgical residency at Baptist Memorial Hospital in Memphis-Georgetown, Tennessee, further honing his surgical skills and clinical expertise. Throughout his career, Dr. Cockrell has been recognized for clinical excellence and strong professional leadership. He received the Harry Casson Award for Outstanding Achievement, a notable honor in podiatry. He is also an active member of the American College of Foot and Ankle Surgeons and the American Podiatric Medical Association. Since 1995, Dr. Cockrell has served continuously on the Tennessee Podiatric Medical Association (TPMA) executive board, holding key roles including scientific chair, treasurer, secretary, vice president and president. He served two consecutive terms as TPMA president from 2001 to 2003, helping guide statewide initiatives to advance podiatric care and improve patient outcomes. In 2015, Dr. Cockrell became the first surgeon in Tennessee to use the Merete Medical Metafix PlantarMax tension-side fixation plate, a German-engineered device designed to improve surgical outcomes in bunion and plantar plate repairs. This innovative technology reflects his commitment to surgical advancements that promote better recovery and positive results. "We are thrilled to welcome Dr. Cockrell to our care team," said Dr. David Farnen, co-owner of Cutting-Edge Foot and Ankle Clinic. "His extensive experience, surgical innovation and patient-centered approach align perfectly with our mission to provide exceptional care to every patient." Dr. Cockrell is accepting new patients at both the Nashville and Brentwood clinics. He specializes in diabetic foot care, wound healing, sports injuries and advanced surgical interventions for complex foot and ankle conditions. His expertise ensures patients receive the highest standard of care for both routine and challenging foot health issues. Cutting-Edge Foot and Ankle Clinic is known for its use of advanced diagnostic tools and personalized podiatry treatment plans tailored to each patient's unique needs. The clinic offers a broad range of services, including minimally invasive procedures, regenerative medicine and custom orthotics. The collaborative team remains committed to delivering high-quality, patient-focused care in a welcoming, compassionate environment. Beyond treatment, the clinic emphasizes patient education about foot and ankle health, empowering individuals with knowledge about prevention, maintenance and treatment options. This holistic approach promotes improved mobility, reduces pain and improves overall quality of life. Whether addressing chronic conditions or acute injuries, the team guides patients every step of the way with expertise and compassion. For appointments or media inquiries, please contact: Cutting-Edge Foot And Ankle Clinic Nashville Location: 3443 Dickerson Pike, Suite 740 Nashville, TN 37207 Brentwood Location: 1001 Healthpark Drive, Suite 330 Brentwood, TN Phone: (615) 866-9639 Website: Hours: Monday-Friday, 8:00 AM - 5:00 PM About Cutting-Edge Foot And Ankle Clinic: Founded by Dr. David Farnen and Dr. Yerusalem Lanier, Cutting-Edge Foot And Ankle Clinic is a leading podiatric practice serving the Middle Tennessee area with locations in Nashville and Brentwood. The practice features a comprehensive team of healthcare providers including Morgan Hubble, MP and Rojin Abdullah, PA, delivering innovative and comprehensive foot and ankle care using the latest medical technologies and treatment approaches. ### For more information about Cutting Edge Foot And Ankle Clinic , contact the company here:Cutting Edge Foot And Ankle Clinic Dr. Yerusalem Lanier DPM615-866-9639yerulanier@ Dickerson Pike, Suite 740, Nashville, TN 37207 CONTACT: Dr. Yerusalem Lanier DPMError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
